Q-omics provides the consensus-scored PABPC5 profile across patient tissues and cancer cell-line models. PABPC5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PABPC5 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PABPC5 RNA expression shows 20,033 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where PABPC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPC5 survival associations across molecular data types. PABPC5 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPC5 RNA expression–survival associations across cancer types. High PABPC5 expression shows unfavorable associations in UVM and KIRP, but favorable associations in KIRC, LGG, ACC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for PABPC5 RNA expression.
This table summarizes PABPC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PABPC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPC5 shows lower tumor expression in KICH, THCA, BLCA, COAD, LUSC and UCEC. The KICH box plot shows higher PABPC5 RNA expression in normal versus tumor tissue (log2 FC = −0.980, t-test p < 0.001).
This table shows molecular features associated with PABPC5 in patient tissues and cancer cell lines. In patient samples, PABPC5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PABPC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
